Drug Profile
Syk kinase inhibitor - Bayer
Alternative Names: Syk tyrosine kinase inhibitor - BayerLatest Information Update: 17 Dec 2003
Price :
$50
*
At a glance
- Originator Bayer
- Class
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 17 Dec 2003 No development reported - Preclinical for Asthma in Europe (unspecified route)
- 17 Jul 2001 Preclinical development for Asthma in Europe (Unknown route)